

ARTICLE

Open Access

Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis

Junlian Gu^{1,2,3}, Shudong Wang⁴, Hua Guo³, Yi Tan^{1,2,3}, Yaqin Liang⁵, Anyun Feng¹, Qiuju Liu⁶, Chendil Damodaran⁷, Zhiguo Zhang⁴, Bradley B. Keller^{3,8}, Chi Zhang^{1,2} and Lu Cai^{1,2,3}

Abstract

Elevated tumor suppressor p53 expression has been associated with heart diseases, including the diabetic heart. However, its precise role in the pathogenesis of diabetic cardiomyopathy (DCM) remains unclear. We hypothesized that the development of DCM is attributed to up-regulated p53-mediated both early cardiac cell death and persistent cell senescence, glycolytic and angiogenic dysfunctions. The present study investigated the effect of p53 inhibition with its specific inhibitor pifithrin- α (PFT- α) on the pathogenesis of DCM and its associated mechanisms. Type 1 diabetes was induced with multiple low doses of streptozotocin. Both hyperglycemic and age-matched control mice were treated with and without PFT- α five times a week for 2 months and then sacrificed at 3 and 6 months post-diabetes. Treatment with PFT- α significantly prevented the progression of diabetes-induced cardiac remodeling and dysfunction (i.e., DCM). Mechanistically, the inhibition of p53 prevented the cardiac apoptosis during early-stage diabetes (0.5 month), attenuated diabetes-induced cell senescence (3 and 6 months), and improved both glycolytic and angiogenic defects by increasing hypoxia-induced factor (HIF)-1 α protein stability and upregulating HIF-1 α transcription of specific target genes at 3 and 6 months after diabetes. Therefore, the targeted inhibition of p53 in diabetic individuals may provide a novel approach for the prevention of DCM.

Introduction

Diabetes mellitus (DM) is one of the major health threats to modern society¹. Among all diabetic complications, cardiovascular diseases are the primary cause of mortality in diabetic patients. One of the important early cardiac responses to diabetes may be the apoptotic death^{2–4}. We and others have shown that diabetes induces cardiac cell death in the hearts of both type 1 and type

2 diabetes (T1DM and T2DM)^{3–7}. The significant increase in cardiomyocyte death is observed at the early stage of T1DM mice induced by streptozotocin (STZ)^{4,7} and cardiac specimens from T2DM patients⁸.

Studies have indicated that p53 and associated apoptosis play important roles in the pathogenesis of mechanical stress and ischemia/reperfusion caused acute cardiac diseases^{9,10}. Accordingly, the role of p53 dependent pathways in the pathogenesis of diabetes associated cardiac cell death and diabetic cardiomyopathy (DCM) is of great interest. For instance, a short-term study tried to determine if p53 promotes cardiac dysfunction in diabetes via excessive mitochondrial respiration-mediated oxidative stress and lipid accumulation at the 4th week after T1DM induction by single injection of high-dose STZ¹¹.

Correspondence: Chi Zhang (zhangchi515@126.com)

¹Ruian Center of Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Ruian, China

²Chinese-American Research Institute for Diabetic Complications, the School of Pharmaceutical Sciences of the Wenzhou Medical University, Wenzhou, China
Full list of author information is available at the end of the article

Edited by G. Melino

© The Author(s) 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

However, this study was unable to definitively answer their questions because: (1) at 4 weeks after STZ treatment, mitochondria damage was most likely due to the direct toxicity of a single high-dose (200 mg/kg) of STZ, rather than diabetes^{12,13}; and (2) changes in cardiac function within a short period after STZ treatment are also most likely due to the direct effect of STZ¹². DCM is a chronic disease, therefore, this short-term study was unable to address whether p53 activation plays an important role in the development of DCM at the later stage of diabetes.

Diabetes impairs glucose uptake and utilization and also decreases adaptive neovascularization (angiogenesis); however, the roles of p53 in the pathogenesis of DCM at later stages of diabetes have never been examined. Recent studies indicated that p53 has broader roles, which include its metabolic regulation in cells under both adaptive physiologic and pathologic disease conditions¹⁴. One example is that p53 is able to dampen glycolysis possibly by disrupting the balance between glycolysis and oxidative phosphorylation¹⁴. In addition, p53 is also able to disrupt glucose import¹⁵ via the pentose phosphate pathway¹⁶.

In the present study we hypothesized that the activation of p53 may both induce cardiac apoptosis at the early stage and also disrupt glycolysis and angiogenesis throughout the pathogenic process. To test this hypothesis, we utilized a T1DM mouse model with STZ as previously described¹⁷. These diabetic mice were treated with or without pifithrin- α (PFT- α), a specific p53 inhibitor, for 2 months. Functional and pathological changes in the heart were examined at the early (0.5 month), middle (3 months), and late (6 months) stages of STZ induced diabetes. To mechanistically investigate the preventive effect of PFT- α on the pathogenesis of DCM, *in vitro* primary cultures of the adult cardiomyocytes were also used with small interfering RNAs (siRNAs) of p53 and murine double minute-2 (MDM2).

Results

General features of diabetic mice with and without PFT- α treatment

To test whether inhibition of p53 prevented DCM, multiple low-dose STZ (MLD-STZ)-induced DM mice and age-matched controls were treated with either PFT- α or a vehicle for 2 months. These mice were sacrificed at 0.5, 3, and 6 months after DM onset. Representative images of the general appearance of mice from each group are shown in Supplemental Fig. 1, which showed disorganized fur that lacked luster in MLD-STZ-induced DM mice compared to control mice. PFT- α treatment completely prevented the occurrence of these effects in DM/PFT- α mice, observed at the 6th month of DM. The body weight was reduced in DM group, which was

recovered in the DM/PFT- α group by PFT- α treatment at either 3 months or 6 months (Supplemental Fig. 2). Echocardiography examination revealed that DM progressively induced cardiac dysfunction, which were observed at the 3 and 6-month time points (Table 1). These echocardiographic changes were partially but significantly prevented in the DM/PFT- α group by PFT- α treatment.

Effect of PFT- α on DM-induced cardiac remodeling, inflammation, and oxidative stress

The ratio of heart weight to tibia length significantly increased in the DM group at the 3 and 6-month time points, which is suggestive of cardiac hypertrophy, an effect that was completely prevented by PFT- α treatment (Fig. 1a). Diabetes-induced cardiac hypertrophy was further confirmed by the observation of enlarged hearts in the experimental mice (Fig. 1b). Hypertrophic cardiomyocytes were evident by semi-quantitative analysis of the myocyte area with wheat germ agglutinin (WGA) staining (Fig. 1c). Morphological hypertrophy was further supported by the upregulation of the molecular hypertrophy markers atrial natriuretic peptide (ANP) and β -myosin heavy chain (β -MHC) at the mRNA (Fig. 1d) and protein levels (Fig. 1e) in the DM mice, but not in the PFT- α /DM mice (Fig. 1a–e).

Sirius red staining revealed significant collagen accumulation in DM mice at 6 months (Fig. 2a), suggesting the induction of cardiac fibrosis. Cardiac fibrosis was confirmed by qRT-PCR and western blot of the pro-fibrotic mediators, connective tissue growth factor (CTGF) and transforming growth factor β 1 (TGF- β 1) (Figs. 2b, c). None of these fibrotic indices were significantly increased in DM/PFT- α mice (Fig. 2a–c).

We next examined cardiac expression of inflammatory cytokines tumor necrosis factor alpha (TNF- α) and interleukin-6 (IL-6) by qRT-PCR (Fig. 3a) and western blot (Fig. 3b). Significantly increased TNF- α and IL-6 mRNA expression and protein levels were noted in the DM group, which was completely prevented by PFT- α treatment.

Oxidative stress has been suggested to play a key role in DM-induced cardiac pathogenesis¹⁸ and was measured by protein nitration and peroxidation with western blot of 3-nitrotyrosine (3-NT) (Figs. 3c) and 4-hydroxy-2-nonenal (4-HNE) (Fig. 3d). Lipid peroxidation was detected using the malondialdehyde (MDA) assay (Fig. 3e). Both oxidative stress indices were significantly increased in the DM mice, but not in the PFT- α /DM mice.

Effect of PFT- α on diabetes-induced cell death and cell senescence

Increased numbers of TUNEL-positive cells were observed in the hearts of DM mice only at 0.5 month after

Table 1 Protective effect of PFT- α on diabetes-induced cardiac dysfunction

	Ctrl	PFT- α	DM	DM/PFT- α
2W				
IVS;d	0.62 \pm 0.02	0.62 \pm 0.03	0.61 \pm 0.02	0.62 \pm 0.04
LVID;d	3.75 \pm 0.03	3.74 \pm 0.05	3.78 \pm 0.02	3.78 \pm 0.04
LVPW;d	0.82 \pm 0.03	0.85 \pm 0.06	0.86 \pm 0.03	0.86 \pm 0.03
IVS;s	1.01 \pm 0.05	1.05 \pm 0.05	1.02 \pm 0.03	1.02 \pm 0.02
LVID;s	2.13 \pm 0.05	2.06 \pm 0.12	2.22 \pm 0.13	2.14 \pm 0.08
LVPW;s	1.28 \pm 0.04	1.30 \pm 0.07	1.29 \pm 0.05	1.31 \pm 0.02
LV Vol;d	59.87 \pm 1.05	59.62 \pm 1.31	61.19 \pm 1.01	61.13 \pm 0.88
LV Vol;s	14.98 \pm 0.92	13.71 \pm 1.52	16.61 \pm 1.24	15.11 \pm 1.47
% EF	75.87 \pm 2.32	77.01 \pm 2.24	72.85 \pm 2.62	75.29 \pm 2.21
% FS	43.62 \pm 1.19	44.98 \pm 2.07	41.23 \pm 1.86	38.57 \pm 1.51
LV Mass	90.77 \pm 2.37	94.40 \pm 4.70	96.74 \pm 4.95	96.54 \pm 4.46
3M				
IVS;d	0.60 \pm 0.02	0.61 \pm 0.03	0.60 \pm 0.02	0.62 \pm 0.02
LVID;d	3.70 \pm 0.02	3.75 \pm 0.02	3.87 \pm 0.05*	3.82 \pm 0.02*
LVPW;d	0.85 \pm 0.03	0.87 \pm 0.04	0.80 \pm 0.04*	0.86 \pm 0.03
IVS;s	1.02 \pm 0.02	1.05 \pm 0.04	0.97 \pm 0.02*	1.03 \pm 0.02
LVID;s	2.01 \pm 0.07	2.02 \pm 0.03	2.65 \pm 0.12*	2.32 \pm 0.05 [†]
LVPW;s	1.27 \pm 0.02	1.30 \pm 0.02	1.28 \pm 0.03	1.31 \pm 0.02
LV Vol;d	57.98 \pm 0.78	59.87 \pm 1.05	65.22 \pm 1.10*	62.69 \pm 1.3 [†]
LV Vol;s	13.13 \pm 0.90	13.11 \pm 0.45	26.75 \pm 1.03*	18.79 \pm 0.95 [†]
% EF	77.39 \pm 1.36	78.10 \pm 1.66	60.26 \pm 2.43*	70.30 \pm 1.83 [†]
% FS	45.35 \pm 1.28	45.99 \pm 1.63	30.76 \pm 1.06*	39.04 \pm 1.24 [†]
LV Mass	89.90 \pm 2.22	96.25 \pm 2.17	98.01 \pm 2.42*	100.41 \pm 1.87*
6M				
IVS;d	0.62 \pm 0.02	0.63 \pm 0.03	0.57 \pm 0.02*	0.63 \pm 0.02 [†]
LVID;d	3.77 \pm 0.02	3.82 \pm 0.06	4.21 \pm 0.02*	3.95 \pm 0.06 [†]
LVPW;d	0.86 \pm 0.03	0.86 \pm 0.05	0.79 \pm 0.03*	0.90 \pm 0.02 [†]
IVS;s	1.03 \pm 0.02	1.04 \pm 0.04	0.97 \pm 0.01*	1.01 \pm 0.06
LVID;s	2.13 \pm 0.03	2.15 \pm 0.10	3.14 \pm 0.10*	2.43 \pm 0.05 [†]
LVPW;s	1.35 \pm 0.03	1.37 \pm 0.02	1.25 \pm 0.02*	1.31 \pm 0.02 [†]
LV Vol;d	60.66 \pm 0.87	63.33 \pm 2.23	79.05 \pm 0.99*	68.03 \pm 2.3 [†]
LV Vol;s	14.87 \pm 0.62	15.28 \pm 1.91	39.10 \pm 3.24*	20.74 \pm 1.0 [†]
% EF	75.47 \pm 1.32	75.93 \pm 2.20	50.58 \pm 3.49*	69.48 \pm 1.83 [†]
% FS	43.55 \pm 1.22	44.04 \pm 1.95	25.49 \pm 2.13*	38.57 \pm 1.51 [†]
LV Mass	95.52 \pm 1.92	102.06 \pm 2.36	105.64 \pm 2.84*	108.57 \pm 2.17*

Notes: *IVS* interventricular septum, *LVID d* left ventricular internal diastolic diameter, *LVID s* left ventricular internal systolic diameter, *LVPW* left ventricular posterior wall, *EF* ejection fraction, *FS* fractional shortening, *LV vol s* left ventricular end systolic volume, *LV vol d* left ventricular end diastolic volume, *LV mass* left ventricular mass. Data are presented as the mean \pm SD ($n = 6$)

*, $p < 0.05$ vs. Ctrl group; [†], $p < 0.05$ vs. DM group






Fig. 1 Effect of PFT-α treatment on diabetes-induced cardiac hypertrophy. **a** Heart weight to tibia length ratio. **b** Heart size. **c** Cardiac tissue FITC-conjugated WGA staining and quantification of myocyte cross-sectional areas (Scale bar = 25 μm). **d**, **e** qRT-PCR and western blot analysis of hypertrophic markers ANP and β-MHC mRNA (**d**) and protein (**e**) expressions. C: Ctrl; P: PFT-α; D: DM; D/P: DM/PFT-α



DM onset compared to control mice, and were almost completely absent after PFT- α treatment (Fig. 4a). Mitochondria-dependent apoptotic cell death is prevalent in the T1DM mouse heart⁴, highlighting the role of mitochondrial cell death pathways in T1DM-induced apoptosis. Thus, p53-mediated-mitochondrial cell death pathway was examined in our PFT- α treatment paradigm. Western blot revealed a significant increase in the Bax to Bcl-2 ratio and apoptosis-inducing factor (AIF) expression, which are both an index of mitochondrial cell death pathway^{19,20}, along with increased level of cleaved caspase-3 in the DM group, but not in the PFT- α /DM mice (Figs. 4b–d).

It should be noted that although there was no significant increase in caspase-3 cleavage and TUNEL-positive cells at late stages of DM (3 and 6 months, Figs. 4a,b), consistent with our and other previous studies^{4,5,7}, Western blot (Fig. 4e) revealed a significant increase in p53 protein expression both at the early stage (0.5 month) and at other time points (3 and 6 months) in DM groups. In addition, a persistent inhibition of p53 expression was observed in the DM/PFT- α group from 0.5 to 6 months after DM onset. These results suggest that the prevention of DCM by inhibition of p53 may be due to both the suppression of early apoptotic cell death and the prevention of later pathogenic effects, such as increased




cell senescence. Therefore, we investigated the effect of PFT-α on cell senescence at the 0.5, 3, and 6-month time points. Diabetes increased cell senescence, as reflected by increased expression of senescence markers (p16INK4A

and p21WAF1/CIP) (Fig. 4f) and senescence-associated β-galactosidase (SA-β-gal) activity (Fig. 4g) at the 3 and 6 months DM time points, and these cell senescence indices were significantly attenuated by PFT-α.

Effect of PFT- α treatment on glucose metabolism and angiogenesis

To further investigate the other pathological effects of p53 activation beyond cell death and senescence, we investigated the effect of PFT- α on the mRNA levels of key glycolytic enzymes including hexokinase 1 (HK-1),

HK-2, pyruvate kinase (PK), enolase 1(ENO1), phospho-fructokinase (PFK), and lactate dehydrogenase (LDH), as well as PK and LDH activities, as previously described²¹. The results showed that PFT- α either preserved or significantly increased the mRNA levels of HK-2, PK, PFK, and LDH as well as the activity of PK and LDH in the






Fig. 4 (continued)


DM/PFT-α mice at the 3 and 6-month time points relative to that in the DM mice (Supplemental Figs. 3a, b; Figs. 5a, b).

Reduced glucose uptake in the diabetic heart is associated with decreased activity of glucose transporters such as glucose transporter (GLUT) 1, and 4^{22,23}. Thus, we determined the protein expression of GLUT-1 and GLUT-4 by immunofluorescence (Fig. 5c) and western blot analysis (Fig. 5d). DM mice at the 3 and 6-month

time points showed a decrease in GLUT-1 and GLUT4 protein expression compared to control mice and PFT-α treatment markedly normalized DM-reduced GLUT-1 and GLUT4 protein expression. In parallel to GLUT-1 and GLUT-4 expression, the high glucose (HG)-treated primary cardiomyocytes showed a reduction in glucose uptake compared to that in the control group, an effect that was largely prevented by PFT-α or p53-siRNA treatment (Supplemental Fig. 4a-c).

The second major function of HIF-1 α is to stimulate cardiac angiogenesis in response to hypoxic conditions such as chronic DM. Insufficiency in blood vessel formation in the diabetic heart is characterized by a

significant reduction in the expression of vascular endothelial growth factor (VEGF) and its receptor, VEGFR2²³. We showed that PFT- α treatment did not induce changes in capillary density in the non-DM myocardium but






Fig. 5 (continued)

significantly prevented DM-induced reduction at the 3 and 6-month time points (Fig. 5e). In addition, consistent with the observed capillary density, a significant reduction in VEGF and VEGFR2 expression was observed in the DM group, but not in the DM/PFT- α group (Fig. 5f).

p53 interacts with HIF-1 α , which facilitates MDM2-dependent ubiquitination and consequent proteasomal degradation in late-stage DM

Defective glycolysis and angiogenesis in the hearts of patients with DM and experimental DM animals have been reported²³. To explore the molecular mechanism of p53 inhibition on glycolysis and angiogenesis, we examined the mRNA and protein expression of HIF-1 α , a key transcription factor for the hypoxic induction of glucose utilization and angiogenic factors, in the hearts of DM mice with and without PFT- α treatment. The results showed that HIF-1 α mRNA levels significantly decreased in the DM group compared to that in the control mice. But PFT- α treatment did not increase its mRNA levels in


DM/PFT- α mice (Fig. 6a). In contrast to HIF-1 α mRNA levels, HIF-1 α protein levels were almost completely normalized by PFT- α treatment in DM mice at the 3 and 6-month time points (Fig. 6b). HIF-1 α immunofluorescence was further confirmed, in which the DM-downregulated cardiac HIF-1 α protein expression in DM mice was prevented by PFT- α treatment (Fig. 6c; Supplemental Fig. 5).

To investigate a potential mechanism by which p53 inhibition resulted in the preservation of HIF-1 α protein expression following PFT- α treatment the half-life of HIF-1 α was analyzed in primary cardiomyocytes under HG conditions. In control-transfected or treated cells, the HIF-1 α protein underwent decay at a half-life of 20–40 min, whereas this was extended beyond 40 min in p53 siRNA-transfected or PFT- α -treated cells (Fig. 6d). These findings indicated that p53 negatively controls the levels of the HIF-1 α protein. To investigate the molecular mechanism by which p53 regulates HIF-1 α protein levels, we next determined whether, similar to p73²⁴, a direct

interaction of p53 with HIF-1 α is involved. Immunoprecipitation using the protein lysate of primary cardiomyocytes revealed the coexistence of p53 and HIF-1 α in the same molecular complex (Fig. 6e). Similarly, protein

interactions were also confirmed by immunoprecipitation of cardiac tissues (Figs. 6f, g).

To determine whether the observed increase in HIF-1 α ubiquitination was a consequence of the p53-HIF1 α






Fig. 6 (continued)

interaction, we then analyzed ubiquitin-HIF-1α levels with or without PFT-α or p53 siRNA treatment. In the presence of the 20 s proteasome inhibitor, MG132, HG strongly increased the expression of the ubiquitinated forms of HIF-1α, and the ubiquitinated level of HIF-1α was significantly reduced by PFT-α or p53 siRNA treatment under HG conditions (Fig. 7a). Thus, p53 promoted HIF-1α ubiquitination, leading to proteasomal degradation, through a protein-protein interaction with HIF-1α.

Ubiquitin conjugation to proteins destined for proteasomal degradation involves a complicated process that includes an E1 Ub-activating enzyme, E2 Ub-conjugating enzyme, and E3 Ub-protein ligase. Multiple E3 Ub-ligase enzymes are responsible for the selection of proteins

destined for the proteasome. MDM2 as one of E3 Ub-protein ligases is able to bind to p73 at the N-terminal region and inhibits tumor angiogenesis by promoting HIF-1α degradation²⁴. We hypothesized that the p53-HIF-1α interaction also facilitates MDM2-dependent HIF-1α ubiquitination, with p53 playing the role of a scaffold protein. First, we detected the protein expression of MDM2 among groups at various time points. Western blot and immunofluorescence analysis indicated the upregulation of MDM2 in the DM groups, but not in the DM/PFT-α groups, at the 3 and 6-month time points relative to that in the control mice (Fig. 7b; Supplemental Fig. 6). At the 3 and 6-month time points, anti-HIF-1α immunoprecipitation with MDM2 from the




Fig. 7 p53 facilitates HIF-1α ubiquitination and consequent proteasomal degradation in an MDM2-dependent manner. **a** HIF-1α polyubiquitination examined by immunoprecipitation and western blot of primary cardiomyocytes in the presence of MG132 with or without PFT-α or p53-siRNA treatment. **b** The MDM2 protein expression detected by western blot analysis. **c, d** The protein-protein interaction between MDM2 and HIF-1α detected at 3 (**c**) and 6 (**d**) months after diabetes onset by immunoprecipitation in vivo. **e** The protein-protein interaction between MDM2 and HIF-1α detected by immunoprecipitation in primary cardiomyocytes after transfection with Ctrl-siRNA or MDM2-siRNA. **f** HIF-1α polyubiquitination examined by immunoprecipitation and western blot in primary cardiomyocytes after transfection with Ctrl-siRNA or MDM2-siRNA. Data expressed as mean ± SD of three independent experiments. **P* < 0.05 vs. Ctrl; #*P* < 0.05 vs. DM

DM group, but not the DM/PFT-α group, displayed significantly higher MDM2 levels in the complex compared to that in the other groups (Figs. 7c, d), thereby suggesting that the interaction of MDM2 with HIF-1α under DM conditions is p53-dependent. A similar

experiment involving selective knockdown of endogenous MDM2 in primary cardiomyocytes resulted in the disruption of the HIF-1α-MDM2 interaction and a reduction in the levels of ubiquitinated HIF-1α when MDM2 was depleted (Figs. 7e, f).

Discussion

This is the first study, to our knowledge, to investigate whether targeting p53 using PFT- α prevents cardiac tissue damage in a long-term T1DM model (until 6 months after diabetes). One major finding is that the prevention by p53 inhibition of DM-induced cardiac remodeling and dysfunction are associated with both attenuation of the early-stage apoptosis and prevention of the persistent cell senescence and glycolytic and angiogenic dysfunction.

We previously reported that DM-induced cardiac apoptosis occurs at an early stage (7–21 days) in mitochondria-dependent manner⁴. In line with these studies, the present study shows that DM induces a significant increase in the number of apoptotic cells, mirrored by increased TUNEL-positive cells, expression of cleaved caspase-3, ratio of Bax to Bcl2 expression, and AIF expression exclusively at the 0.5 month time-point (Fig. 4). PFT- α treatment resulted in a significant reduction of apoptotic effect at 0.5 month after DM. It is noticed that, at 3 and 6 months after DM, although there is still a higher p53 expression in the DM group compared to control, the rate of DM-induced apoptosis was significantly low, as indicated by the levels of cleaved caspase-3 expression and the results of the TUNEL assay (Fig. 4).

To date, no report has explained why a low apoptotic rate is observed in late-stage DM despite significant cardiac dysfunction. Our explanation is that cardiac cells may respond via apoptotic death at early stage but respond via cell senescence at the relatively late stages since significant increases in senescent markers (Fig. 4). Adult cardiomyocytes are terminally differentiated, and thus cell loss can be detrimental to cardiac function. When cardiomyocytes are lost, collagen is deposited to replace apoptotic cardiomyocytes²⁵, which lead to cardiac fibrosis and dysfunction. Although senescent cells were not removed like apoptotic cells, these cells do not have normal function and even generate inflammatory cytokines, leading to microenvironmental inflammatory responses and oxidative stress (Fig. 3)²⁶; To support this notion, a recent study reports that enhancing clearance of senescent cells could reverse effects of chemotoxicity and aging in aged mice by preventing p53 nuclear transcription²⁷. In our model we also confirmed inhibition of p53 have significantly reduced senescent cells from 3 to 6 months after the onset of DM.

Late-stage DM hearts are also characterized by downregulation of HIF-1 α (Fig. 6). HIF-1 α is a master transcription factor that confers cardioprotection by triggering the activation of specific downstream genes²¹. Stabilization of HIF-1 α by inhibition of prolyl hydroxylase or by treatment with CoC₁₂ reduced cardiac infarct size and cardiac dysfunction after global ischemia/reperfusion²⁸. However, whether inhibition of p53 can preserve

HIF-1 α activity in the DM heart has not yet been investigated. An earlier study showed that p53 causes cardiac hypertrophy during pressure overload by inhibition of HIF-1 α ²⁹. Another study demonstrated that p53 promotes the ubiquitin-mediated degradation of HIF-1 α via recruitment of an E3 ubiquitin–protein ligase (MDM2) and subsequently inhibits the angiogenic switch during tumorigenesis³⁰. Here we demonstrated for the first time in the mouse model of type 1 diabetes conditions that p53 also directly increases the expression of MDM2 and recruits MDM2 to HIF-1 α , thereby facilitating its ubiquitin-dependent proteasomal degradation and inhibiting its transactivation properties under DM conditions. Of note, after p53 inhibitor treatment, HIF-1 α protein stability and activity was significantly improved (Figs. 5, 6, and 7).

Except for inducing apoptotic cell death, p53 also has multiple functions via upregulating HIF-1 α transcription of its specific downstream genes including the glucose transporters, GLUT1 and GLUT4. Previous reports have shown that the expression of GLUT-1 and GLUT-4 are reduced in the DM heart^{22,23}, which in turn leads to reduction in cardiac glucose influx and uptake in patients with DM. Similar to the results of previous studies, STZ-induced DM significantly reduced both GLUT-1 and GLUT-4 protein expression and glucose uptake in the heart (Figs. 5c, d and Supplemental Fig. 4), which can be reversed by p53 inhibition. In addition to glucose transporters, key glycolytic enzymes such as PK and LDH play important roles in cellular glucose metabolism, thereby maintaining the downhill glucose concentration gradient that is necessary for glucose transport into cells²¹. The reduction in activity of these glycolytic enzymes is believed to be a mechanism in DCM, and restoration of cardiac glycolysis improves DM heart function²³. The present study determined that PFT- α treatment increases the activity of key glycolytic enzymes such as PK and LDH in the DM heart via the upregulation of HIF-1 α (Figs. 5a, b and Supplemental Figs. 3a, b).

Another important gene that is regulated by HIF-1 α is VEGF. VEGF is a key regulator of angiogenesis in the myocardium. Impaired myocardial VEGF expression along with inadequate angiogenesis has been shown to be a major cellular and metabolic response in diabetic cardiomyopathy³¹. In the present study, we found that the inhibition of p53 results in the restoration of DM-associated reduced VEGF and reduced VEGF receptor levels, which subsequently leads to the improvement of capillary density in the DM heart (Figs. 5e, f).

One innovative finding of the present study is that treatment of DM mice with PFT- α for the first 2 months elicited a persistent cardioprotective effect on DM, which was observed not only during the treatment with PFT- α at 0.5 month, but also at 1 and 4 months after

discontinuation of PFT- α treatment (i.e., the 3th and 6th month of DM). Although the underlying mechanism for the persistence of cardiac protection by short inhibition of p53 remains unclear, we assume that it may be related to the epigenetic regulation of p53 expression based on the following facts. PFT- α was reported able to reverse cancer-downregulated the activity of DNA methyltransferases (DNMTs) DNMT1 and DNMT3a in HCT-116 colon cancer cells, suggesting the possible for p53 directly or indirectly to increase DNMTs activity³². Reportedly PFT- α blocks interaction of p53 with transcriptional cofactor p300 and downregulates histone acetylation after DNA damage³³.

In summary, we demonstrated here for the first time that inhibition of p53 prevents the functional and pathological abnormalities of the heart in a T1DM mouse model, through multiple mechanisms, as illustrated in Supplemental Fig. 7. During the early stage of DM (0.5 month), inhibition of p53 reduces cardiac mitochondrial cell death, whereas during late-stage DM (3–6 months), inhibition of p53 prevents DM-induced cardiac senescence and impairment of glucose metabolism and angiogenesis. Regarding the improvement of glucose metabolism and angiogenesis by inhibition of p53 is most likely mediated by increasing HIF-1 α protein stability and its transcription of specific target genes. However, its direct clinical importance remains elusive and thus further exploration is warranted.

Materials and methods

Animals and treatment

FVB male mice were purchased from The Jackson Laboratory. All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of Louisville. FVB mice were injected intraperitoneally with MLD-STZ (50 mg/kg body weight) [Sigma-Aldrich, St. Louis, MO, USA] daily for five consecutive days. We used MLD-STZ-induced T1DM mouse model because although our previous studies showed that a single high dose of STZ (150–210 mg/kg) induces T1DM, these diabetic mice have high mortality due to the systemic toxicity of high-dose STZ^{4,34}, whereas MLD-STZ induces T1DM in mice without mortality^{17,35}. Mice with hyperglycemia (blood glucose levels \geq 250 mg/dL) were defined as diabetic. These mice were divided into four groups ($n = 6$): non-diabetic (Ctrl), PFT- α -treated non-diabetic (PFT- α), diabetic mice (DM), and DM with PFT- α (DM/PFT- α). PFT- α (Sigma-Aldrich) was intraperitoneally administered at 1.1 mg/kg five times a week for 2 months based on published studies³⁶, and then mice were kept for additional 4 months without PFT- α treatment. Mice were sacrificed at 0.5, 3, and 6 months post-diabetes for various measurements. 6 months after diabetes as the longest time-point was selected since our

previous studies have extensively confirmed the well-developed DCM at this time-point^{17,18,34,35}. Usage of the selective p53 inhibitor, PFT- α , rather than p53 knockout mice, in the present study because of (1) the similar effects of PFT- α and p53 deficient mice on p53 function^{36–38}, (2) inhibition of p53 after diabetes onset; (3) also inhibition of p53 only for short period (2 months) to investigate whether temporal inhibition can provide a persistent effect after stopping use of inhibitor. In addition, compared to genetic approaches, the pharmacological inhibition of p53 in diabetic individuals may provide a novel approach for the prevention of DCM in the future.

Echocardiography

Transthoracic echocardiography was performed using a high-resolution imaging system for small animals (Vevo 770, Visual Sonics) as previously described^{34,35,39}.

Western blot and quantitative real-time PCR (qRT-PCR)

Western blot and qRT-PCR were performed according to our previous studies^{4,17,39}. Antibodies and primers are listed in Supplemental Table 1 and 2.

Histological staining

Cardiac fibrosis was detected with a mixture of 0.1% Sirius red F3BA and 0.25% Fast Green FCF and quantified using Pro Plus 6.0 software³⁹. Cardiac cell death was detected by Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining and presented as the number of TUNEL-positive cells per 10³ cells⁴⁰. For myocyte cross-sectional histological analysis, sections were stained with Alexa Fluor[®] 488 conjugated WGA and calculated using ImageJ software³⁹. SA- β -gal activity was measured with a SA- β -gal staining kit (Cell Signaling, Danvers, MA, USA).

Biochemical measurement of lipid peroxides

To detect lipid peroxide accumulation in the heart, the tissue protein was determined by measuring thiobarbituric acid reactivity, reflected by the content of MDA formed during acid hydrolysis of the lipid peroxide compound, as previously described³⁹.

Immunofluorescence

Immunofluorescence was performed as previously described^{17,39}. Antibodies are listed in Supplemental Table 1. Images were captured with Nikon microscope (Nikon, Melville, NY, USA) and quantified using the NIH ImageJ 1.43 software.

Primary cardiomyocyte isolation and treatment

Adult mouse primary cardiomyocytes were isolated and cultured as previously described^{35,41}. Primary cardiomyocytes were treated for 48 h with HG (25 mM glucose)

and PFT- α (30 μ M) or a specific siRNAs against p53 and MDM2 (Invitrogen, Carlsbad, CA, USA). The siRNA transfections in adult mouse cardiomyocytes were performed using Lipofectamine[®] 3000 (Invitrogen) following the manufacturer's instructions as previously described³⁵.

Immunoprecipitation

Immunoprecipitation was performed with heart tissues (30 mg from each mouse) or cell lysates (500 μ g) lysed in immunoprecipitation buffer using a Pierce Co-Immunoprecipitation kit (Pierce Biotechnology Ltd., Rockford, IL, USA) as previously described^{42–44}. Immunocomplexes were determined using specific antibodies as indicated.

Statistical analysis

Data from all replicates were presented as the mean \pm SD ($n \geq 6$ in each group). Comparisons among various groups were performed by two-way ANOVA, followed by post-hoc pairwise repetitive comparisons using Tukey's test with Origin 9.0 Lab data analysis and graphing software. Statistical significance was considered as $P < 0.05$.

Acknowledgements

We thank LetPub for its linguistic assistance during the preparation of this manuscript. This work was supported in part by research grants from the National Science Foundation of China (81370917, 81670767 to CZ; 81273509, to YT; 81600631 to JG; 81302860 to QL; 81570338, to ZZ), the Medical Technology of Zhejiang Province (2015KYB236), and the American Diabetes Association (1-15-B5-018, to L.C.).

Author details

¹Ruian Center of Chinese-American Research Institute for Diabetic Complications, the Third Affiliated Hospital of the Wenzhou Medical University, Ruian, China. ²Chinese-American Research Institute for Diabetic Complications, the School of Pharmaceutical Sciences of the Wenzhou Medical University, Wenzhou, China. ³the Department of Pediatrics of the University of Louisville, Pediatrics Research Institute, Louisville, KY 40202, USA. ⁴Department of Cardiology, the First Hospital of Jilin University, Changchun 130021, China. ⁵Department of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. ⁶Department of Hematology, the First Hospital of Jilin University, Changchun 130021, China. ⁷Department of Urology, the University of Louisville, Louisville, KY, USA. ⁸Kosair Charities Pediatric Heart Research Program, Cardiovascular Innovation Institute, University of Louisville, Louisville, KY 40202, USA

Authors' contributions

JG performed experiments and wrote the manuscript draft. SW, HG, YT, YL, AF, QL, CD, and ZZ participated in data collection and analysis. LC and CZ participated in the project design and direct the progression of experiments. CZ, CD, LC, and BK participated in manuscript revision. All of the authors approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing financial interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version of this article (<https://doi.org/10.1038/s41419-017-0093-5>) contains supplementary material.

Received: 20 July 2017 Revised: 1 October 2017 Accepted: 9 October 2017
Published online: 23 January 2018

References

- Shaw, J. E., Sicree, R. A. & Zimmet, P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res. Clin. Pract.* **87**, 4–14 (2010).
- Boudina, S. & Abel, E. D. Diabetic cardiomyopathy revisited. *Circulation*. **115**, 3213–3223 (2007).
- Monkemann, H. et al. Early molecular events in the development of the diabetic cardiomyopathy. *Amino. Acids*. **23**, 331–336 (2002).
- Cai, L. et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. *Diabetes*. **51**, 1938–1948 (2002).
- Cai, L. & Kang, Y. J. Cell death and diabetic cardiomyopathy. *Cardiovasc. Toxicol.* **3**, 219–228 (2003).
- van de Weijer, T., Schrauwen-Hinderling, V. B. & Schrauwen, P. Lipotoxicity in type 2 diabetic cardiomyopathy. *Cardiovasc. Res.* **92**, 10–18 (2011).
- Kajstura, J. et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. *Diabetes*. **50**, 1414–1424 (2001).
- Frustaci, A. et al. Myocardial cell death in human diabetes. *Circ. Res.* **87**, 1123–1132 (2000).
- Yoshida, Y. et al. p53-Induced inflammation exacerbates cardiac dysfunction during pressure overload. *J. Mol. Cell. Cardiol.* **85**, 183–198 (2015).
- Zhang, Y. et al. Inhibition of p53 after acute myocardial infarction: reduction of apoptosis is counteracted by disturbed scar formation and cardiac rupture. *J. Mol. Cell. Cardiol.* **50**, 471–478 (2011).
- Nakamura, H. et al. p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation. *Circ Heart Fail* **5**, 106–115 (2012).
- Wold, L. E. & Ren, J. Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. *Biochem. Biophys. Res. Commun.* **318**, 1066–1071 (2004).
- Raza, H. & John, A. Streptozotocin-induced cytotoxicity, oxidative stress and mitochondrial dysfunction in human hepatoma HepG2 cells. *Int J Mol Sci* **13**, 5751–5767 (2012).
- Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. *Cell* **126**, 107–120 (2006).
- Schwartzberg-Bar-Yoseph, F., Armoni, M. & Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. *Cancer Res.* **64**, 2627–2633 (2004).
- Jiang, P. et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. *Nat. Cell. Biol.* **13**, 310–316 (2011).
- Bai, Y. et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. *J. Mol. Cell. Cardiol.* **57**, 82–95 (2013).
- Cai, L. et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. *Diabetes*. **54**, 1829–1837 (2005).
- Martinou, J. C. & Youle, R. J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. *Dev. Cell*. **21**, 92–101 (2011).
- Susin, S. A. et al. Molecular characterization of mitochondrial apoptosis-inducing factor. *Nature*. **397**, 441–446 (1999).
- Lall, R. et al. Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response. *Cell. Death. Differ.* **21**, 836–844 (2014).
- Kainulainen, H. et al. In vivo glucose uptake and glucose transporter proteins GLUT1 and GLUT4 in heart and various types of skeletal muscle from streptozotocin-diabetic rats. *Biochim. Biophys. Acta.* **1225**, 275–282 (1994).
- Xue, W. et al. Cardiac-specific overexpression of HIF-1[alpha] prevents deterioration of glycolytic pathway and cardiac remodeling in streptozotocin-induced diabetic mice. *Am. J. Pathol.* **177**, 97–105 (2010).

24. Amelio, I. et al. TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1 α degradation. *Proc Natl Acad Sci U S A* **112**, 226–231 (2015).
25. Harvey, P. A. & Leinwand, L. A. The cell biology of disease: cellular mechanisms of cardiomyopathy. *J. Cell. Biol.* **194**, 355–365 (2011).
26. Correia-Melo, C., Hewitt, G. & Passos, J. F. Telomeres, oxidative stress and inflammatory factors: partners in cellular senescence? *Longev Healthspan* **3**, 1 (2014).
27. Baar, M. P. et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. *Cell* **169**, 132–147 e116 (2017).
28. Natarajan, R. et al. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. *Circ. Res.* **98**, 133–140 (2006).
29. Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. *Nature*. **446**, 444–448 (2007).
30. Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes Dev.* **14**, 34–44 (2000).
31. Yoon, Y. S. et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. *Circulation*. **111**, 2073–2085 (2005).
32. Schneider-Stock, R. et al. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. *J. Pharmacol. Exp. Ther.* **312**, 525–536 (2005).
33. Culmsee, C. et al. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. *J. Neurosci.* **23**, 8586–8595 (2003).
34. Zhang, J. et al. Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. *Clin. Sci.* **130**, 625–641 (2016).
35. Zhang, C. et al. Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. *Diabetologia*. **58**, 1937–1948 (2015).
36. Hoshino, A. et al. Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic beta-cell function in diabetes. *Proc Natl Acad Sci U S A* **111**, 3116–3121 (2014).
37. Derdak, Z. et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. *J. Hepatol.* **58**, 785–791 (2013).
38. Shimizu, I. et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. *Cell. Metab.* **15**, 51–64 (2012).
39. Gu, J. et al. Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy. *Diabetes*. **66**, 529–542 (2017).
40. Tan, Y. et al. Angiotensin II plays a critical role in alcohol-induced cardiac nitrate damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner. *J. Am. Coll. Cardiol.* **59**, 1477–1486 (2012).
41. Luo, J. et al. Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure. *Am. J. Physiol. Heart. Circ. Physiol.* **293**, H3673–H3684 (2007).
42. Gu, J. et al. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. *Eur. J. Cancer*. **50**, 1184–1194 (2014).
43. Zhang, Z. et al. Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway. *J. Mol. Cell. Cardiol.* **77**, 42–52 (2014).
44. Wang, S. et al. Zinc rescues obesity-induced cardiac hypertrophy via stimulating metallothionein to suppress oxidative stress-activated BCL10/CARD9/p38 MAPK pathway. *J. Cell. Mol. Med.* **21**, 1182–1192 (2017).